Pfizer Inc. to Present New Data Highlighting Ongoing Research at 2012 Meeting of the American Association for Cancer Research

NEW YORK--(BUSINESS WIRE)--Pfizer Oncology will present data from a variety of preclinical and clinical studies of Pfizer’s early-stage compounds, including data from Pfizer’s investigational antibody-drug conjugate (ADC) portfolio and research evaluating several molecules targeting novel pathways that play a crucial role in basic cellular functions, at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago, IL, from March 31-April 4.
MORE ON THIS TOPIC